TY - JOUR T1 - Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 PCR positivity: primary, contributing, or incidental COVID-19 JF - medRxiv DO - 10.1101/2022.04.12.22273760 SP - 2022.04.12.22273760 AU - Anne F. Voor in ’t holt AU - Cynthia P. Haanappel AU - Janette Rahamat – Langendoen AU - Richard Molenkamp AU - Els van Nood AU - Leon M. van den Toorn AU - Robin P. Peeters AU - Annemarie M.C. van Rossum AU - Juliëtte A. Severin Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/04/18/2022.04.12.22273760.abstract N2 - SARS-CoV-2 Omicron variants BA.1 and BA.2 seem to show reduced clinical severity. We classified 172 COVID-19 Omicron patient admissions. 66.2% of patients were admitted with primary or admission-contributing COVID-19. We therefore must be careful to base healthcare and public health decisions on the total number of hospitalized COVID-19 patients alone.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The medical ethical research committee of the Erasmus MC University Medical Center gave ethical approval for this work (MEC-2021-0845-A-0002).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -